Updated Jul 16, 2026
Huizenga Theodore Alan has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $45K.
Theodore Alan Huizenga is the Senior Vice President and Chief Accounting Officer at Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on treatments for rare diseases. He has been involved in the financial operations of the company, contributing to its growth and compliance.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-24 | RARE | Ultragenyx Pharmaceutical Inc. | A — Grant or award | 20.2K | $0.00 | |
| 2026-03-03 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 1.6K | $22.80 | $37K |
| 2026-03-03 | RARE | Ultragenyx Pharmaceutical Inc. | F — Tax withholding / forfeiture | 148 | $23.39 | $3K |
| 2025-12-30 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 85 | $34.38 | $3K |
| 2025-09-18 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 64 | $29.17 | $2K |
| 2025-09-05 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 84 | $31.39 | $3K |
| 2024-12-11 | RARE | Ultragenyx Pharmaceutical Inc. | G — Bona-fide gift | 648 | $0.00 |
Theodore Alan Huizenga is the Senior Vice President and Chief Accounting Officer at Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on treatments for rare diseases. He has been involved in the financial operations of the company, contributing to its growth and compliance.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 4 open-market sales ($45K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Huizenga Theodore Alan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.